rfhealthЗдравоохранение Российской ФедерацииHealth care of the Russian Federation0044-197X2412-0723Federal Scientific Center of Hygiene named after F.F. Erisman10.46563/0044-197X-2020-64-6-318-323rfhealth-232Research ArticleПРОБЛЕМЫ СОЦИАЛЬНО ЗНАЧИМЫХ ЗАБОЛЕВАНИЙPROBLEMS OF SOCIALLY SIGNIFICANT DISEASESРегиональный опыт оценки медицинской технологии на примере противовирусной терапии хронического гепатита С препаратами прямого противовирусного действияRegional experience in assessing medical technology on the example of antiviral therapy for chronic hepatitis C with direct antiviral drugshttps://orcid.org/0000-0002-7214-4340КорниловаЕкатерина БорисовнаKornilovaEkaterina B.

Канд. мед. наук, вед. науч. сотр. ГБУ «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения города Москвы», 115184, Москва.

e-mail: ekaterinakornilova2017@gmail.com

MD, Ph.D., leading researcher, Research Institute of Health Organization and Medical Management of Moscow Healthcare Department, Moscow, 115088, Russia.

e-mail: ekaterinakornilova2017@gmail.com

ekaterinakornilova2017@gmail.comhttps://orcid.org/0000-0002-2437-298XХоловня-ВолосковаМ. Э.Hołownia-VoloskovaMalwina Ewanoemail@neicon.ruhttps://orcid.org/0000-0002-0798-5493АрьковаЕ. С.Ar’KovaElena S.noemail@neicon.ruhttps://orcid.org/0000-0002-7668-378XРосликД. А.RoslikDmitriy A.noemail@neicon.ruhttps://orcid.org/0000-0001-6304-4594ЛучининЕ. А.LuchininEvgenii A.noemail@neicon.ruhttps://orcid.org/0000-0003-1825-1871ЗавьяловА. А.ZavyalovAleksandr A.noemail@neicon.ruГБУ «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения города Москвы»РоссияResearch Institute for Healthcare Organization and Medical Management of Moscow Healthcare DepartmentRussian FederationГБУ «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения города Москвы»; Department of Experimental and Clinical PharmacologyРоссияResearch Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department; Department of Experimental and Clinical Pharmacology, Medical University of WarsawRussian Federation202001012021646318323Copyright © Корнилова Е.Б., Холовня-Волоскова М.Э., Арькова Е.С., Рослик Д.А., Лучинин Е.А., Завьялов А.А., 20212021Корнилова Е.Б., Холовня-Волоскова М.Э., Арькова Е.С., Рослик Д.А., Лучинин Е.А., Завьялов А.А.Kornilova E.B., Hołownia-Voloskova M.E., Ar’Kova E.S., Roslik D.A., Luchinin E.A., Zavyalov A.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rfhealth.ru/jour/article/view/232Введение

Введение. Препараты прямого противовирусного действия (ПППД) радикально изменили парадигму лечения хронического гепатита С (ХГС) и социальный прогноз для инфицированных лиц и для общества в целом. Однако данная медицинская технология остается малодоступной из-за высокой абсолютной стоимости для систем здравоохранения, отсутствия оценки в конкретном регионе России и соотнесения с результатами применяемых вариантов противовирусной терапии.

Цель исследования - определение наиболее экономически эффективного варианта лекарственного обеспечения ПППД для лечения ХГС.

Материал и методы

Материал и методы. На основании изученных данных о популяции взрослых пациентов с диагнозом ХГС, получающих лекарственное обеспечение за счет бюджетных средств г. Москвы, выполнен фармакоэкономический анализ лекарственной терапии ПППД.

Результаты

Результаты. Экономически обосновано применение новых пангенотипных ПППД для лечения ХГС у клинически гетерогенной популяции взрослых россиян с 1-6 генотипами вируса гепатита С. Оба альтернативных сценария продемонстрировали преимущество по сравнению с базовым сценарием в виде экономии финансовых средств в размере 66 028 192,45 руб. и 83 647 819,27 руб. и увеличение числа эффективно пролеченных пациентов на 197 и 287 человек в год соответственно.

Заключение

Заключение. Увеличение доли новых ПППД в программах лекарственного обеспечения позволит повысить эффективность использования финансовых ресурсов и увеличить доступность ПППД, что в итоге может привести к достижению эпидемиологического эффекта в популяционном масштабе.

Introduction

Introduction. Such medical technology like a direct antiviral drugs for treatment for chronic hepatitis C (CHC) remains inaccessible due to high absolute cost for health care systems, lack of assessment in specific region of Russian Federation and correlation with results of used antiviral therapy options.

The purpose of the study is to determine most cost-effective option of drug provision with direct antiviral drugs for the treatment of chronic hepatitis C.

Material and methods

Material and methods. Based on the population of chronic hepatitis C adult patients receiving medications at expense of Moscow budget funds, was performed a pharmacoeconomic analysis of drug therapy with direct antiviral drugs.

Results

Results. The use of new pangenotypic direct antiviral drugs for the treatment of CHC in a clinically heterogeneous population of Russian adults with 1-6 genotypes of the hepatitis C virus is economically justified. Both alternative scenarios demonstrated an advantage over the baseline scenario in the form of financial savings of 66,028,192. 45 rubles and 83,647,819.27 rubles and an increase in the number of effectively treated patients by 197 and 287 people per year, respectively.

Conclusion

Conclusion. An increase in the share of new direct antiviral drugs in drug supply programs will increase the efficiency of the use of financial resources and increase the availability of direct antiviral drugs, which may ultimately lead to the achievement of an epidemiological effect on a population scale.

препараты прямого противовирусного действияглекапревир/пибрентасвирвелпатасвир/софосбувирхронический гепатит Санализ влияния на бюджетфармакоэкономический анализdirect antiviral agentglecaprevir/pibrentasvirvelpatasvir/sofosbuvirchronic hepatitis Cbudget impact analysispharmacoeconomic analysisReferencesВОЗ. Гепатит C. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-cWHO. Hepatitis C. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-cВОЗ. Всемирный день борьбы с гепатитом 2020 г. Available at: https://www.who.int/ru/campaigns/world-hepatitis-day/2020WHO. World Hepatitis Day 2020. Available at: https://www.who.int/campaigns/world-hepatitis-day/2020Росстат. Оценка численности постоянного населения на 1 января 2020 года и в среднем за 2019 год Росстат. Available at: https://rosstat.gov.ru/folder/12781Rosstat. Estimate of the permanent population as of January 1, 2020 and the average for 2019. Available at: https://rosstat.gov.ru/folder/12781 (in Russian)Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander W.J., et al. The natural history of community-acquired hepatitis C in the united states. N. Engl. J. Med. 1992; 327(27): 1899-905. https://doi.org/10.1056/NEJM199212313272702Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander W.J., et al. The natural history of community-acquired hepatitis C in the united states. N. Engl. J. Med. 1992; 327(27): 1899–905. https://doi.org/10.1056/NEJM199212313272702Shiff E.R. The alcoholic patient with Hepatitis C Virus infection. Am. J. Med. 1999; 107(6B): 10-5. https://doi.org/10.1016/S0002-9343(99)00393-9.Shiff E.R. The alcoholic patient with Hepatitis C Virus infection. Am. J. Med. 1999; 107(6B): 10–5. https://doi.org/10.1016/S0002-9343(99)00393-9.Armstrong G.L., Alter M.J., McQuillan G.M., Margolis H.S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000; 31(3): 777-82. https://doi.org/10.1002/hep.510310332.Armstrong G.L., Alter M.J., McQuillan G.M., Margolis H.S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000; 31(3): 777–82. https://doi.org/10.1002/hep.510310332.Chung R.T. AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis c virus infection. Clin. Infect. Dis. 2018; 67(10):1477-92. https://doi.org/10.1093/cid/ciy585Chung R.T. AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis c virus infection. Clin. Infect. Dis. 2018; 67(10):1477–92. https://doi.org/10.1093/cid/ciy585EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatology. 2020; 73(5): 1170-218. https://doi.org/10.1016/j.jhep.2020.08.018.EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatology. 2020; 73(5): 1170–218. https://doi.org/10.1016/j.jhep.2020.08.018.WHO. Global health sector strategy on viral hepatitis, 2016-2021. Available at: http://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1WHO. Global health sector strategy on viral hepatitis, 2016–2021. Available at: http://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1Berden F.A., Aaldering B.R., Groenewoud H., IntHout J., Kievit W., Drenth J.P. Identification of the best direct-acting antiviral regimen for patients with hepatitis C Virus genotype 3 infection: a systematic review and network meta-analysis. Clin. Gastroenterol. Hepatol. 2017; 15(3): 349-59. https://doi.org/10.1016/j.cgh.2016.10.034Berden F.A., Aaldering B.R., Groenewoud H., IntHout J., Kievit W., Drenth J.P. Identification of the best direct-acting antiviral regimen for patients with hepatitis C Virus genotype 3 infection: a systematic review and network meta-analysis. Clin. Gastroenterol. Hepatol. 2017; 15(3): 349–59. https://doi.org/10.1016/j.cgh.2016.10.034Majumdar A., Kitson M.T., Roberts S.K. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment. Pharmacol. Ther. 2016; 43(12): 1276-92. https://doi.org/10.1111/apt.13633Majumdar A., Kitson M.T., Roberts S.K. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment. Pharmacol. Ther. 2016; 43(12): 1276–92. https://doi.org/10.1111/apt.13633Poordad F., Schiff E.R., Vierling J.M., Landis C., Fontana R.J., Yang R., et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016; 63(5): 1493-505. https://doi.org/10.1002/hep.28446Poordad F., Schiff E.R., Vierling J.M., Landis C., Fontana R.J., Yang R., et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016; 63(5): 1493–505. https://doi.org/10.1002/hep.28446Wei L., Jia J.D., Wang F.S., Niu J.Q., Zhao X.M., Mu S., et al. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study. J. Gastroenterol. Hepatol. 2019; 34(1): 12-21. https://doi.org/10.1111/jgh.14509Wei L., Jia J.D., Wang F.S., Niu J.Q., Zhao X.M., Mu S., et al. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study. J. Gastroenterol. Hepatol. 2019; 34(1): 12–21. https://doi.org/10.1111/jgh.14509Kwo P., Gane E.J., Peng C.Y., Pearlman B., Vierling J.M., Serfaty L., et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017; 152(1): 164-75. https://doi.org/10.1053/j.gastro.2016.09.045Kwo P., Gane E.J., Peng C.Y., Pearlman B., Vierling J.M., Serfaty L., et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017; 152(1): 164–75. https://doi.org/10.1053/j.gastro.2016.09.045Abergel A., Asselah T., Mallat A., Chanteranne B., Faure F., Larrey D., et al. Phase 3, multicenter open-label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naive, HCV GT1b-infected patiénts, with non-severe fibrosis. Liver Int. 2020; 40(8): 1853-9. https://doi.org/10.1111/liv.14502Abergel A., Asselah T., Mallat A., Chanteranne B., Faure F., Larrey D., et al. Phase 3, multicenter open-label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naive, HCV GT1b-infected patiénts, with non-severe fibrosis. Liver Int. 2020; 40(8): 1853–9. https://doi.org/10.1111/liv.14502Huang C.F., Hung C.H., Cheng P.N., Bair M.J., Huang Y.H., Kao J.H., et al. An open-label, randomized, active-controlled trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive patients with chronic hepatitis C genotype 1b infection and mild fibrosis (EGALITE Study): impact of baseline viral loads and NS5A resistance-associated substitutions. J. Infect. Dis. 2019; 220(4): 557-66. https://doi.org/10.1093/infdis/jiz154Huang C.F., Hung C.H., Cheng P.N., Bair M.J., Huang Y.H., Kao J.H., et al. An open-label, randomized, active-controlled trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive patients with chronic hepatitis C genotype 1b infection and mild fibrosis (EGALITE Study): impact of baseline viral loads and NS5A resistance-associated substitutions. J. Infect. Dis. 2019; 220(4): 557–66. https://doi.org/10.1093/infdis/jiz154Zeuzem S., Serfaty L., Vierling J., Cheng W., George J., Sperl J., et al. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J. Gastroenterol. 2018; 53(5): 679-88. https://doi.org/10.1007/s00535-018-1429-3Zeuzem S., Serfaty L., Vierling J., Cheng W., George J., Sperl J., et al. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J. Gastroenterol. 2018; 53(5): 679–88. https://doi.org/10.1007/s00535-018-1429-3Djambazov S., Slavchev G., Encheva M., Mitova R., Vekov T. Comparative effectiveness of pan-genotypic therapies for the treatment of patients with hepatitis C virus infection in Bulgaria. J. Comp. Eff. Res. 2019; 8(7): 455-9. https://doi.org/10.2217/cer-2018-0143Djambazov S., Slavchev G., Encheva M., Mitova R., Vekov T. Comparative effectiveness of pan-genotypic therapies for the treatment of patients with hepatitis C virus infection in Bulgaria. J. Comp. Eff. Res. 2019; 8(7): 455–9. https://doi.org/10.2217/cer-2018-0143Zeuzem S., Foster G.R., Wang S., Asatryan A., Gane E., Feld J.J., et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N. Engl. J. Med. 2018; 378(4): 354-69. https://doi.org/10.1056/NEJMoa1702417Zeuzem S., Foster G.R., Wang S., Asatryan A., Gane E., Feld J.J., et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N. Engl. J. Med. 2018; 378(4): 354–69. https://doi.org/10.1056/NEJMoa1702417Takehara T., Sakamoto N., Nishiguchi S., Ikeda F., Tatsumi T., Ueno Y., et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J. Gastroenterol. 2019; 54(1): 87-95. https://doi.org/10.1007/s00535-018-1503-xTakehara T., Sakamoto N., Nishiguchi S., Ikeda F., Tatsumi T., Ueno Y., et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J. Gastroenterol. 2019; 54(1): 87–95. https://doi.org/10.1007/s00535-018-1503-xGhany M.G., Morgan T.R. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020; 71(2): 686-721. https://doi.org/10.1002/hep.31060Ghany M.G., Morgan T.R. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020; 71(2): 686–721. https://doi.org/10.1002/hep.31060Foster G.R., Afdhal N., Roberts S.K., Bräu N., Gane E.J., Pianko S., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N. Engl. J. Med. 2015; 373(27): 2608-17. https://doi.org/10.1056/NEJMoa1512612Foster G.R., Afdhal N., Roberts S.K., Bräu N., Gane E.J., Pianko S., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N. Engl. J. Med. 2015; 373(27): 2608–17. https://doi.org/10.1056/NEJMoa1512612Forns X., Lee S.S., Valdes J., Lens S., Ghalib R., Aguilar H., et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect. Dis. 2017; 17(10): 1062-8. https://doi.org/10.1016/S1473-3099(17)30496-6Forns X., Lee S.S., Valdes J., Lens S., Ghalib R., Aguilar H., et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect. Dis. 2017; 17(10): 1062–8. https://doi.org/10.1016/S1473-3099(17)30496-6Asselah T., Kowdley K.V., Zadeikis N., Wang S., Hassanein T., Horsmans Y., et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with Hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin. Gastroenterol. Hepatol. 2018; 16(3): 417-26. https://doi.org/10.1016/j.cgh.2017.09.027Asselah T., Kowdley K.V., Zadeikis N., Wang S., Hassanein T., Horsmans Y., et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with Hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin. Gastroenterol. Hepatol. 2018; 16(3): 417–26. https://doi.org/10.1016/j.cgh.2017.09.027Корнилова Е.Б., Холовня-Волоскова М.Э., Корнилов М.Н., Завьялов А.А. Оценка экономической эффективности стратегии лекарственного обеспечения больных гепатитом С в г. Москве. Проблемы социальной гигиены, здравоохранения и истории медицины. 2020; 28(S2): 1154-61. https://doi.org/10.32687/0869-866X-2020-28-s2-1154-1161Kornilova E.B., Kholovnya-Voloskova M.E., Kornilov M.N., Zav’yalov A.A. Evaluation of the cost-effectiveness of the strategy for drug supply for hepatitis C patients in Moscow. Problemy sotsial’noy gigieny, zdravookhraneniya i istorii meditsiny. 2020; 28(S2): 1154–61. https://doi.org/10.32687/0869-866X-2020-28-s2-1154-1161 (in Russian)Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в городе Москве в 2019 году». М.; 2020.State report «On the state of sanitary and epidemiological welfare of the population in the city of Moscow in 2019». Moscow; 2020. (in Russian)Vademecum. Москва в 2020 году полностью перейдет на безинтерфероновые схемы терапии гепатита С. Available at: https://vademec.ru/news/2019/07/17/moskva-v-2020-godu-polnostyu-pereydet-na-bezinterferonovye-skhemy-terapii-gepatita-s/Vademecum. Moscow will fully switch to interferon-free hepatitis C treatment regimens in 2020. Available at: https://vademec.ru/news/2019/07/17/moskva-v-2020-godu-polnostyu-pereydet-na-bezinterferonovye-skhemy-terapii-gepatita-s/ (in Russian)Нурмухаметова E.A. Оказание специализированной медицинской помощи больным хроническим вирусным гепатитом С в городе Москве. Доклад в рамках XVII Ассамблеи «Здоровье Москвы». Московская медицина. 2018; (S): 93.Nurmukhametova E.A. Providing specialized medical care for patients with chronic viral hepatitis C in Moscow. Report in the framework of the XVII Assembly «Health of Moscow». Moskovskaya meditsina. 2018; (S): 93. (in Russian)Пименов Н.Н., Комарова С.В., Карандашова И.В., Цапкова Н.Н., Волчкова Е.В., Чуланов В.П. Гепатит С и его исходы в России: анализ заболеваемости распространенности и смертности до начала программы элиминации инфекции. Инфекционные болезни. 2018; 16(3): 37-45. https://doi.org/10.20953/1729-9225-2018-3-37-45Pimenov N.N., Komarova S.V., Karandashova I.V., Tsapkova N.N., Volchkova E.V., Chulanov V.P. Hepatitis С and its outcomes in Russia: analysis of incidence, prevalence and mortality rates before the start of the programme of infection elimination. Infektsionnye bolezni. 2018; 16(3): 37–45. https://doi.org/10.20953/1729-9225-2018-3-37-45 (in Russian)Lawitz E., Poordad F., Gutierrez J.A., Wells J.T., Landaverde C.E., Evans B., et al. Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial. Hepatology. 2017; 65(2): 439-50. https://doi.org/10.1002/hep.28877Lawitz E., Poordad F., Gutierrez J.A., Wells J.T., Landaverde C.E., Evans B., et al. Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial. Hepatology. 2017; 65(2): 439–50. https://doi.org/10.1002/hep.28877EASL recommendations on treatment of hepatitis C 2018. J. Hepatol. 2018; 69(2): 461-511. https://doi.org/10.1016/j.jhep.2018.03.026EASL recommendations on treatment of hepatitis C 2018. J. Hepatol. 2018; 69(2): 461–511. https://doi.org/10.1016/j.jhep.2018.03.026

The authors declare that there are no conflicts of interest present.